EnteroBiotix strengthens its executive team
Privately-held Scotland-based EnteroBiotix has announced the appointments of Dr James Barnes as chief operating officer (COO) and Chris Lea as chief financial officer (CFO).
Dr Barnes has 18 years’ early and late phase drug development and business operations leadership experience, spanning several therapeutic areas. He joins the company from BerGenBio, a biotech company developing innovative drugs for oncology and serious respiratory infections, where he was COO. Dr Barnes previously worked at Vertex Pharmaceuticals (Nasdaq: VRTX) as director of regulatory affairs where he led the strategy development of several breakthrough products. He also held several positions at clinical research organizations including ICON Clinical Research.
Mr Lea joins EnteroBiotix as CFO and company secretary. He was previously CFO of AIM-listed Cambridge Nutritional Sciences (formerly Omega Diagnostics Group).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze